Latest Information Update: 30 Apr 2012
At a glance
- Originator PGxHealth
- Mechanism of Action Adenosine A2B receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma; Type 2 diabetes mellitus
Most Recent Events
- 31 Dec 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
- 31 Dec 2011 Discontinued - Phase-II for Asthma in USA (PO)